everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...6364656667686970717273...132133»
  • ||||||||||  everolimus / Generic mfg., pimasertib (AS703026) / EMD Serono, Sanofi
    Journal:  mTOR inhibitor everolimus reduces invasiveness of melanoma cells. (Pubmed Central) -  Aug 5, 2020   
    Slightly less profound reduction of invasiveness was obtained for the combinations of an mTOR inhibitor-everolimus with ERK1/2 inhibitor-U126 or MEK inhibitor-AS-703026 and in the case of MMPs activity decrease for PI3 K inhibitor-LY294002 and AKT inhibitor-MK-2206. The simultaneous use of everolimus or another new generation rapalog with selected inhibitors of crucial signaling kinases seems to be a promising concept in cancer treatment.
  • ||||||||||  metformin / Generic mfg., everolimus / Generic mfg.
    Journal:  Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment. (Pubmed Central) -  Aug 5, 2020   
    The simultaneous use of everolimus or another new generation rapalog with selected inhibitors of crucial signaling kinases seems to be a promising concept in cancer treatment. Considering the promising effects of the everolimus and metformin combination in NET cells, our results provide a rationale for its use in NET patients.
  • ||||||||||  metformin / Generic mfg., everolimus / Generic mfg., sirolimus / Generic mfg.
    Review, Journal:  Fasting and rapamycin: diabetes versus benevolent glucose intolerance. (Pubmed Central) -  Aug 2, 2020   
    No hyperglycemic effects of rapamycin/everolimus have been detected in healthy people. For antiaging purposes, rapamycin/everolimus can be administrated intermittently (e.g., once a week) in combination with intermittent carbohydrate restriction, physical exercise, and metformin.
  • ||||||||||  prednisolone / Generic mfg., hydrocortisone / Generic mfg., everolimus / Generic mfg.
    Clinical, P2 data, Journal:  Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study. (Pubmed Central) -  Jul 29, 2020   
    This prospective phase-II study showed that two steroid-containing mouthrinses substantially reduced incidences of all-grade and grade ≥2 stomatitis and related oral adverse events (AEs), and the number of everolimus dose-delays and/or dose-reduction in metastatic breast cancer (MBC) patients receiving everolimus treatment plus an aromatase inhibitor. Both oral rinses were well tolerated and demonstrated similar efficacy.Prophylactic use of steroid mouth rinse provides a cost-effective option that substantially decreases the incidence and severity of mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis and related oral AEs as well as the need for dose modification in MBC patients undergoing treatment with an mTOR inhibitor.
  • ||||||||||  everolimus / Generic mfg.
    Review, Journal:  Current Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Intervention. (Pubmed Central) -  Jul 29, 2020   
    EXCEL trial evaluated the same treatment option in low to intermediate SYNTAX score population with third-generation everolimus DES platform as PCI option...In low to medium SYNTAX score, particularly in patients without diabetes mellitus, PCI remains a viable option. Future trials focusing on evaluating subset of patients who would benefit from one particular revascularization option in comparison with other is warranted.
  • ||||||||||  everolimus / Generic mfg.
    Clinical, Review, Journal, IO Biomarker:  Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). (Pubmed Central) -  Jul 28, 2020   
    In addition, chemotherapy remains an option, with temozolomide and capecitabine being one of the most popular doublets to use...Strategies for treatment selection in patients with PanNETs based on patient, disease, or drug characteristics is provided, as well as a summary of current evidence on prognostic and predictive biomarkers. Future perspectives are discussed, focusing on current and forthcoming challenges and unmet needs of patients with these rare tumours.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, everolimus / Generic mfg.
    Journal, PD(L)-1 Biomarker:  Applied precision medicine in metastatic pancreatic ductal adenocarcinoma. (Pubmed Central) -  Jul 24, 2020   
    One patient was treated with nintedanib and achieved stable disease for 6 months. Based on our observations, precision medicine approaches are feasible and implementable in clinical routine and may provide molecular-based therapy recommendations for mPDAC.
  • ||||||||||  everolimus / Generic mfg., Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    [VIRTUAL] Aggregated analysis of treatment and survival outcome of all metastatic renal cell carcinoma patients treated from 2014 to 2018 in the Veneto region, Italy (On-Demand) -  Jul 24, 2020 - Abstract #ESMO2020ESMO_2370;    
    First-line pazopanib and sunitinib had a median DT of 10.5 and 9.7 mo (32.3% censored, p=0.51), and median OS of 28.6 and 26.2 mo (54.6% censored, p=0.61), respectively...Nivolumab and cabozantinib had a longer DT both in second line (compared to axitinib, everolimus and sorafenib (p<0.0001)) and third line (compared to everolimus or sorafenib, (p<0.0001)), although medians were not reached with all drugs (Table)...Table: 1604P DT, OS and average monthly cost of drugs per patient (NR=not reached) Legal entity responsible for the study: The authors. Funding: IPSEN.
  • ||||||||||  everolimus / Generic mfg., Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
    Journal:  Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. (Pubmed Central) -  Jul 22, 2020   
    RNA and whole-exome sequencing revealed RAS-mediated TORC1 activation in a subset of neratinib-resistant models. DNA sequencing of HER2-mutant tumors clinically refractory to neratinib, as well as circulating tumor DNA profiling of patients who progressed on neratinib, showed enrichment of genomic alterations that converge to activate the mTOR pathway.
  • ||||||||||  everolimus / Generic mfg.
    Clinical, Journal:  Efficacy of dextran and peptide-everolimus bi-directional stent. (Pubmed Central) -  Jul 21, 2020   
    Cell adhesion and proliferation of peptide-everolimus-dextran were inhibited at A10, and human umbilical vein endothelial cell was found to proliferate with cell adhesion. On conclusion, dextran and peptide-everolimus bidirectional stent is effective in re-endothelialization and inhibition of cell proliferation.
  • ||||||||||  metformin / Generic mfg., everolimus / Generic mfg., doxorubicin hydrochloride / Generic mfg.
    [VIRTUAL] Modulation of MCF-7 cell sensitivity to anticancer agents by targeting glycolysis (On-Demand) -  Jul 21, 2020 - Abstract #ESMO2020ESMO_356;    
    Glucose deprivation and 2DOG sensitized MCF-7 cells to two only drugs, metformin and oligomycin A. Glucose deprivation causes a 1000-fold increase in the antiproliferative effects of oligomycin A in hormone-dependent MCF-7 breast cancer cells...Legal entity responsible for the study: The authors. Funding: Russian Foundation for Basic Research (agreements 18-29-09017, studies of ERα signaling and 19-015-00058, studies of everolimus) and the Russian Science Foundation (agreement 20-13-00402, studies of CAIX inhibitor).
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, everolimus / Generic mfg.
    Review, Journal, PD(L)-1 Biomarker, IO Biomarker:  PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. (Pubmed Central) -  Jul 21, 2020   
    A study investigating everolimus (Rad001) with cisplatin and radiotherapy has reported promising 2-year progression free survival and overall survival rates of 85% and 92%. Further clinical trials should follow.
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    Enrollment open, Metastases:  CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) -  Jul 20, 2020   
    P1,  N=12, Recruiting, 
    Further clinical trials should follow. Not yet recruiting --> Recruiting